A New Reason to be Bullish About Sarepta Therapeutics

NEW YORK (TheStreet) --I've written about Sarepta Therapeutics (SRPT) twice over the past month, with good reason. Despite a modest $327 million market capitalization, recent clinical data suggest that the company's lead drug candidate eteplirsen may be an effective treatment for Duchenne muscular dystrophy (DMD) -- a progressive disease that leaves patients wheelchair bound by their teens and dead shortly thereafter.

My first article highlighted risks that I thought my colleague Adam Feuerstein missed in his bullish coverage. My second addressed comments I received from institutional investors who own Sarepta. They thought I was overly critical of eteplirsen even though I had declared Sarepta to be "a reasonable long position for biotech investors with a healthy appetite for risk."

Last week, I learned an important tidbit that I don't think is widely known by the investment community: Sarepta's Phase IIb study of eteplirsen remained effectively blinded for far longer than 24 weeks.

See if (SRPT) is in our portfolio

That's important and potentially very good news for Sarepta. Before I explain why, let's recap the eteplirsen study to date:

Continued here:
A New Reason to be Bullish About Sarepta Therapeutics